Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.

Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33524-5. doi: 10.1016/j.jtho.2019.09.196. [Epub ahead of print]

PMID:
31605799
2.
3.

[Vaccines for the treatment of non-small cell lung cancer].

Leduc C, Quoix E.

Rev Mal Respir. 2019 Mar;36(3):415-425. doi: 10.1016/j.rmr.2018.12.003. Epub 2019 Mar 20. Review. French.

PMID:
30902445
4.

Time to give a rest to cetuximab in the treatment of advanced non-small cell lung carcinoma?

Quoix E, Westeel V.

J Thorac Dis. 2018 Sep;10(Suppl 26):S3043-S3046. doi: 10.21037/jtd.2018.08.33. No abstract available.

5.

KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.

Renaud S, Guerrera F, Seitlinger J, Reeb J, Voegeli AC, Legrain M, Mennecier B, Santelmo N, Falcoz PE, Quoix E, Chenard MP, Weingertner N, Beau-Faller M, Massard G.

Clin Lung Cancer. 2018 Nov;19(6):e919-e931. doi: 10.1016/j.cllc.2018.08.005. Epub 2018 Aug 22.

PMID:
30217639
6.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Bennouna J, Barlesi F, Do P, Dumont P, Cadranel J, Debieuvre D, Hilgers W, Molinier O, Quoix E, Raimbourg J, Langlais A, Morin F, Souquet PJ.

ESMO Open. 2018 Jul 23;3(5):e000394. doi: 10.1136/esmoopen-2018-000394. eCollection 2018.

7.

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients.

Emprou C, Le Van Quyen P, Jégu J, Prim N, Weingertner N, Guérin E, Pencreach E, Legrain M, Voegeli AC, Leduc C, Mennecier B, Falcoz PE, Olland A, Santelmo N, Quoix E, Massard G, Guenot D, Chenard MP, Beau-Faller M.

Cancer Med. 2018 May 29. doi: 10.1002/cam4.1545. [Epub ahead of print]

8.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.

ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. eCollection 2016.

9.

Lung segmentectomy: does it offer a real functional benefit over lobectomy?

Charloux A, Quoix E.

Eur Respir Rev. 2017 Oct 25;26(146). pii: 170079. doi: 10.1183/16000617.0079-2017. Print 2017 Dec 31. Review.

10.

Comorbidities in the management of patients with lung cancer.

Leduc C, Antoni D, Charloux A, Falcoz PE, Quoix E.

Eur Respir J. 2017 Mar 29;49(3). pii: 1601721. doi: 10.1183/13993003.01721-2016. Print 2017 Mar. Review.

11.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.

Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025.

12.

Programmed death of chemotherapy in non-small-cell lung cancer?

Leduc C, Quoix E.

Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1. Epub 2016 Dec 13. No abstract available.

PMID:
27979385
13.

Diagnosis of Jejunal Metastases from Lung Cancer Using Capsule Endoscopy.

Leduc C, Prim N, Mennecier B, Delvaux M, Gangi A, Quoix E.

Case Rep Oncol. 2016 Sep 13;9(3):526-529. eCollection 2016 Sep-Dec.

14.

Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.

Gass-Jégu F, Gschwend A, Gairard-Dory AC, Mennecier B, Tebacher-Alt M, Gourieux B, Quoix É.

Lung Cancer. 2016 Sep;99:76-8. doi: 10.1016/j.lungcan.2016.06.012. Epub 2016 Jun 14. Review.

PMID:
27565918
15.

[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].

Zapata E, Mennecier B, Leduc C, Chatron E, Quoix E.

Rev Pneumol Clin. 2016 Oct;72(5):300-304. doi: 10.1016/j.pneumo.2016.05.004. Epub 2016 Aug 22. French.

PMID:
27561974
16.

Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry.

Truntzer P, Antoni D, Santelmo N, Schumacher C, Falcoz PE, Quoix E, Massard G, Noël G.

Rep Pract Oncol Radiother. 2016 Sep-Oct;21(5):427-34. doi: 10.1016/j.rpor.2016.03.006. Epub 2016 May 5.

17.

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.

Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur Respir J. 2016 Sep;48(3):861-72. doi: 10.1183/13993003.01695-2015. Epub 2016 Jun 23.

18.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.

19.

Post-operative survival of patients with lung cancer.

Quoix E.

Lancet Oncol. 2016 Jun;17(6):697-698. doi: 10.1016/S1470-2045(16)30031-6. Epub 2016 Apr 27. No abstract available.

PMID:
27132211
20.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE.

Lancet Oncol. 2016 May;17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11.

21.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM.

Lancet Oncol. 2016 Feb;17(2):212-223. doi: 10.1016/S1470-2045(15)00483-0. Epub 2015 Dec 23.

PMID:
26727163
22.

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10.

PMID:
26682871
23.

[Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer].

Milleron B, Westeel V, Gounant V, Wislez M, Quoix E.

Bull Cancer. 2016 Jan;103(1):66-72. doi: 10.1016/j.bulcan.2015.11.001. Epub 2015 Dec 9. Review. French.

PMID:
26682626
24.

Is there a role for e-cigarettes in smoking cessation?

Leduc C, Quoix E.

Ther Adv Respir Dis. 2016 Apr;10(2):130-5. doi: 10.1177/1753465815621233. Epub 2015 Dec 14. Review.

25.

[MANAGEMENT OF LUNG CANCER IN ELDERLY].

Leduc C, Quoix E.

Rev Prat. 2015 Sep;65(7):945-9. French.

PMID:
26619732
26.

Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

Renaud S, Schaeffer M, Voegeli AC, Legrain M, Guérin E, Meyer N, Mennecier B, Quoix E, Falcoz PE, Guénot D, Massard G, Noël G, Beau-Faller M.

Future Oncol. 2016 Jan;12(1):59-70. doi: 10.2217/fon.15.273. Epub 2015 Nov 30.

PMID:
26616848
27.

Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE.

Guffroy A, Dima A, Nespola B, Poindron V, Sibilia J, Herbrecht R, De Sèze J, Habersetzer F, Andres E, Quoix E, Ohlmann P, Cribier B, Langer B, Martin T, Pasquali JL, Goetz J, Korganow AS.

Joint Bone Spine. 2016 May;83(3):330-4. doi: 10.1016/j.jbspin.2015.07.002. Epub 2015 Oct 1.

PMID:
26433710
28.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.

Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Eur Respir J. 2015 Nov;46(5):1440-50. doi: 10.1183/13993003.02358-2014. Epub 2015 Sep 17.

29.

Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG).

Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, Aapro M.

Eur J Cancer. 2015 Nov;51(17):2491-500. doi: 10.1016/j.ejca.2015.08.005. Epub 2015 Sep 1. Review.

PMID:
26340809
30.

Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.

Rotonda C, Anota A, Mercier M, Bastien B, Lacoste G, Limacher JM, Quoix E, Bonnetain F.

PLoS One. 2015 Jul 24;10(7):e0132568. doi: 10.1371/journal.pone.0132568. eCollection 2015.

31.

Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations.

Berghmans T, Meert AP, Quoix E.

Eur Respir J. 2015 Jul;46(1):19-21. doi: 10.1183/09031936.00021315. No abstract available.

32.

Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.

Carpentier O, Selvaggi L, Jégu J, Purohit A, Prim N, Velten M, Quoix E.

Clin Lung Cancer. 2015 Nov;16(6):496-506. doi: 10.1016/j.cllc.2015.05.001. Epub 2015 May 13.

PMID:
26071190
33.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavolé A, Mazières J, Toffart AC, Langlais A, Morin F, Zalcman G.

Lung Cancer. 2015 Aug;89(2):139-45. doi: 10.1016/j.lungcan.2015.05.016. Epub 2015 May 27.

PMID:
26059274
34.

[Safety culture assessment in a university pulmonary medicine department].

Leduc C, De Blay F, Kessler R, Quoix E, Kuteifan K.

Rev Mal Respir. 2015 Sep;32(7):715-27. doi: 10.1016/j.rmr.2015.02.006. Epub 2015 May 27. French.

PMID:
26026239
35.

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification.

Weingertner N, Meyer N, Voegeli AC, Guenot D, Renaud S, Massard G, Falcoz PE, Olland A, Mennecier B, Gaub MP, Lindner V, Ghnassia JP, Quoix E, Chenard MP, Beau-Faller M.

Pathology. 2015 Jun;47(4):320-8. doi: 10.1097/PAT.0000000000000269.

PMID:
25938344
36.

[Stereotactic body radiation radiotherapy for oligometastatic non-small cell lung cancer (NSCLC): A case report].

Leduc C, Antoni D, Quoix É, Noël G.

Cancer Radiother. 2015 May;19(3):192-7. doi: 10.1016/j.canrad.2014.12.007. Epub 2015 Apr 1. French.

PMID:
25841992
37.

No impact of passive smoke on the somatic profile of lung cancers in never-smokers.

Couraud S, Debieuvre D, Moreau L, Dumont P, Margery J, Quoix E, Duvert B, Cellerin L, Baize N, Taviot B, Coudurier M, Cadranel J, Missy P, Morin F, Mornex JF, Zalcman G, Souquet PJ; BioCAST/IFCT-1002 study investigators.

Eur Respir J. 2015 May;45(5):1415-25. doi: 10.1183/09031936.00097314. Epub 2015 Mar 5.

38.

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation.

Schaller A, Beau-Faller M, Mennecier B, Renaud-Picard B, Weingertner N, Massard G, Quoix E.

Case Rep Oncol. 2014 Nov 19;7(3):769-73. doi: 10.1159/000369526. eCollection 2014 Sep-Dec.

39.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT); French Cooperative Thoracic Intergroup IFCT.

Ann Oncol. 2015 May;26(5):908-14. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.

PMID:
25688059
40.

Perception of lung cancer among the general population and comparison with other cancers.

Mazières J, Pujol JL, Kalampalikis N, Bouvry D, Quoix E, Filleron T, Targowla N, Jodelet D, Milia J, Milleron B.

J Thorac Oncol. 2015 Mar;10(3):420-5. doi: 10.1097/JTO.0000000000000433.

41.

Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients.

Truntzer P, Antoni DN, Santelmo N, Schumacher C, Falcoz PE, Quoix E, Steib JP, Massard G, Noël G.

Radiat Oncol. 2014 Nov 26;9:259. doi: 10.1186/s13014-014-0259-6.

42.

Adherence and patients' attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies.

Barthélémy P, Asmane-De la Porte I, Meyer N, Duclos B, Serra S, Dourthe LM, Amé S, Litique V, Giron C, Goldbarg V, Fornecker L, Quoix E, Kurtz JE.

Oncology. 2015;88(1):1-8. doi: 10.1159/000366226. Epub 2014 Sep 18.

PMID:
25247774
43.

Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.

Petit-Jean E, Buclin T, Guidi M, Quoix E, Gourieux B, Decosterd LA, Gairard-Dory AC, Ubeaud-Séquier G, Widmer N.

Ther Drug Monit. 2015 Feb;37(1):2-21. doi: 10.1097/FTD.0000000000000097. Review.

PMID:
24831652
44.

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

Wislez M, Barlesi F, Besse B, Mazières J, Merle P, Cadranel J, Audigier-Valette C, Moro-Sibilot D, Gautier-Felizot L, Goupil F, Renault A, Quoix E, Souquet PJ, Madroszyck A, Corre R, Pérol D, Morin F, Zalcman G, Soria JC.

J Clin Oncol. 2014 Apr 20;32(12):1256-61. doi: 10.1200/JCO.2013.53.1525. Epub 2014 Mar 17.

PMID:
24638013
45.

[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française].

Girard N, Gounant V, Mennecier B, Greillier L, Cortot AB, Couraud S, Besse B, Brouchet L, Castelnau O, Ferretti GR, Frappé P, Khalil A, Lefebure P, Laurent F, Liebart S, Margery J, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; groupe de travail multidisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française.

Rev Mal Respir. 2014 Jan;31(1):91-103. doi: 10.1016/j.rmr.2013.10.641. Epub 2014 Jan 10. French. No abstract available.

PMID:
24461451
46.

Reply to letter.

Westeel V, Quoix E, Zalcman G, Milleron B.

Eur J Cancer. 2014 Feb;50(3):678. doi: 10.1016/j.ejca.2013.11.019. Epub 2013 Dec 10. No abstract available.

PMID:
24331956
47.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J.

Ann Oncol. 2014 Jan;25(1):126-31. doi: 10.1093/annonc/mdt418. Epub 2013 Nov 26.

48.

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique.

Eur Respir J. 2014 Jan;43(1):240-9. doi: 10.1183/09031936.00048213. Epub 2013 Oct 10.

49.

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).

Westeel V, Quoix E, Puyraveau M, Lavolé A, Braun D, Laporte S, Bigay-Game L, Pujol JL, Ozenne G, Rivière A, Douillard JY, Lebeau B, Debieuvre D, Poudenx M, David P, Molinier O, Zalcman G, Lemarié E, Morin F, Depierre A, Milleron B; Intergroupe Francophone de Cancérologie Thoracique.

Eur J Cancer. 2013 Aug;49(12):2654-64. doi: 10.1016/j.ejca.2013.04.013. Epub 2013 Jun 1.

PMID:
23735703
50.

[An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].

Guillerme F, Clavier JB, Schumacher C, Falcoz PE, Bourrhala K, Santelmo N, Hassler S, Schott R, Quoix E, Massard G, Noël G.

Cancer Radiother. 2013 Jul-Aug;17(4):272-81. doi: 10.1016/j.canrad.2013.01.021. Epub 2013 May 24. French.

PMID:
23712043

Supplemental Content

Support Center